Malignant brain tumors are classified into primary and secondary (metastatic) brain tumors. Despite recent advancements in conventional therapies, such as surgery, radiation therapy, and chemotherapy, the prognoses for these tumors remain dismal. A variety of immunotherapy clinical trials are being conducted for both primary and secondary malignant brain tumors, including vaccine, checkpoint blockade, adoptive cell transfer, and oncolytic virus approaches.